Forendo Pharma→Organon
Acquisition · Cash · OGN · announced Nov 11, 2021
Announced
Nov 11, 2021
Closed
Dec 13, 2021
Economics
Cash()
Pre-deal · pre-deal mark: 2021, year precision · Organon press release — Forendo Pharma acquisition, 2021
$75M upfront + up to $270M development milestones + $600M commercial milestones (total potential ~$954M)
Target
Forendo Pharma
Reproductive Health · Clinical / therapeutic
HQ Turku, Finland · Founded 2016
Clinical-stage drug development for endometriosis and PCOS — first-in-class HSD17B1 inhibitor (FOR-6219)
- Organon.com - press release (Nov 11, 2021)
- Business Wire - acquisition completion (Dec 13, 2021)
Acquirer
Organon (OGN)
Reproductive Health
HQ Jersey City, NJ
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Novel endometriosis treatment (HSD17B1 inhibitor) — first-in-class tissue-specific approach without impacting systemic hormone levels; pipeline includes PCOS program
Evidence ladder
Secondary (press / IR)
Business Wire (Dec 13, 2021)
Secondary (press / IR)
Organon.com press release
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/tm2131080d1_ex99-1.htm
Open source
Limitations
- $75M upfront + up to $270M development milestones + $600M commercial milestones (total potential ~$954M)
- Pre-deal valuation sourced from: Organon press release — Forendo Pharma acquisition, 2021. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Myovant Sciences | Sumitovant Biopharma (Sumitomo Pharma) | Oct 24, 2022 | ||
| Generate Life Sciences | CooperSurgical (CooperCompanies) | Nov 10, 2021 |
Other verified deals by Organon
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Dermavant Sciences | Organon | Sep 18, 2024 | Dermatology | |
| Alydia Health | Organon (via Merck spinoff) | Mar 30, 2021 | Maternal Health |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Forendo Pharma (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.